scholarly journals A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis

QJM ◽  
2008 ◽  
Vol 101 (4) ◽  
pp. 299-306 ◽  
Author(s):  
A.W. Morgan ◽  
G. Hale ◽  
P.R.U.B. Rebello ◽  
S.J. Richards ◽  
H.-C. Gooi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Biological Therapy

scholarly journals AB0063 DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: A BIOMARKER SCREENING PILOT STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1062.3-1063
Author(s):  
J. Baloun ◽  
A. Pekacova ◽  
H. Mann ◽  
J. Vencovský ◽  
K. Pavelka ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Plasma Proteins ◽  
Biological Therapy ◽  
Signs And Symptoms ◽  
Proteome Profiling ◽  
Potential Biomarker ◽  
Sensitivity Data ◽  
Definition Of ◽  
New Biomarkers

Background:Despite modern therapeutic approaches, many patients with rheumatoid arthritis (RA) remain symptomatic after several cycles of treatment and may become so called Difficult-To-Treat (D2T)1. D2T RA is a multifactorial condition in which different factors may be major determinants of the persistence of signs and symptoms, which is seldom caused by drug resistance only2. Discovering new biomarkers is necessary to develop tailored therapies that will be effective in an individual patient at each stage of the disease.Objectives:The primary aim of this pilot study was to validate a target proteomic technique for the proteome profiling of the two cohorts of RA patients and controls. Moreover, we searched for potential plasma biomarker(s) predicting D2T RA.Methods:Seven RA patients with persistent remission on biological therapy in two consecutive examinations 12 wks apart (mean age 59.6±14 yrs), seven D2T RA patients fulfilling proposed EULAR definition of D2T RA1 (mean age 59.3±13 yrs), and six healthy controls (mean age 58.8±15 yrs) were included in this study. All subjects were females and their samples were collected before starting biological therapy. We employed Thermo Orbitrap Fusion paired with nano-flow UHPLC Dionex Ultimate 3000. Prior to quantification, 125 plasma proteins were modified by Peptiquant Plus Human kit to increase the sensitivity. Data were analysed by ANOVA and Tukey`s posthoc test with false-discovery-rate adjustment.Results:The target proteome profiling reliably quantified 92 from 125 labelled proteins. Our follow-up statistical analysis revealed ten plasma proteins, which significantly differed among groups. Notably, we found significantly different plasma levels of paraoxonase/arylesterase 1 (PON1), an esterase with an antioxidant characteristic preventing lipid peroxidation3, between RA patients and controls and between RA patients with persistent remission and D2T RA patients.Conclusion:Using target proteome profiling technique, we demonstrated PON1 as a potential biomarker of D2T RA. However, these results have to be validated on a larger cohort.References:[1]Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR definition of difficult-To-Treat rheumatoid arthritis. Annals of the Rheumatic Diseases 2021;80:31-5.[2]de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford, England) 2018 Jul 1;57(7):1135-1144.[3]Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clinical Rheumatology 2007;26:342-8.Acknowledgements:This research was supported by MHCR No. 023728 and authors thank Proteomics Service Laboratory, Faculty of Science, Charles University for performing the LC–MS/MS analysis.Disclosure of Interests:None declared

SAT0201 Treatment Adherence in Rheumatoid Arthritis (RA) Patients Followed in a Specific Biological Therapy Unit. a Pilot Study: Table 1.

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 728.2-729
Author(s):  
N. Mena-Vazquez ◽  
S. Manrique-Arija ◽  
L. Yunquera ◽  
I. Ureña-Garnica ◽  
L. Cano-García ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Treatment Adherence ◽  
Biological Therapy

FRI0196 Comparison between ultrasonographic and clinical disease activity of rheumatoid arthritis in patients two years treated with anti tnf biological therapy

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A438.2-A438
Author(s):  
S. Z. Prodanovic ◽  
G. Radunovic ◽  
S. Zivojinovic ◽  
S. Seric ◽  
N. Damjanov ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Biological Therapy ◽  
Clinical Disease ◽  
Clinical Disease Activity

CP-078 Optimisation of biological therapy in established rheumatoid arthritis patients in real life clinical practice

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A34.2-A34
Author(s):  
M Cárdenas ◽  
P Font ◽  
S De la Fuente ◽  
MC Castro-Villegas ◽  
M Romero-Gómez ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Biological Therapy ◽  
Real Life ◽  
Established Rheumatoid Arthritis

scholarly journals AB1176 UTILITY OF REDOSER TOOL IN DOSE OPTIMIZATION OF BIOLOGICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1879.2-1879
Author(s):  
A. M. Cabezas-Lucena ◽  
M. Morales-Águila ◽  
S. Manrique Arija ◽  
C. Fuego-Varela ◽  
L. Cano Garcia ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Dose Reduction ◽  
Biological Therapy ◽  
Activity Index ◽  
Standard Dose ◽  
Disease Evolution ◽  
Independent Variables ◽  
Outpatient Unit ◽  
Baseline Activity

Background:Objectives:To describe the characteristics of patients with rheumatoid arthritis (RA) in dose reduction of biological therapy (BT) in clinical practice and identify possible factors associated with the time in dose reduction and verify the utility of REDOSER tool.Methods:Design:A retrospective, observational longitudinal study under conditions of clinical practice.Patients:RA in BT dose reduction between 2007- 2019 were selected. Inclusion criteria: RA according to ACR 2010 criteria which have been initiated BT dose reduction. Patients with BT are followed prospectively every 3-4 months in a specialized outpatient unit of BT dose reduction with a pre-established protocol for data collection and registered in a database.Variables: Primary:Time in reduction: was defined as the time in which patients maintained the BT optimization andRelapse at 12 and 24 months: percentage of patients who, after starting BT optimization, return to the previous or standard dose.Secondary variables:REDOSER:Appropriate, Doubtful and Inappropriate (If dose reduction was adequate according to the REDOSER tool applied retrospectively were evaluated). Other variables: Demographic, clinical-analytical: time of disease evolution, RF, anti CCP antibodies, Number of Tender Joints, Number of swollen joints, erosions, activity index (DAS28, SDAI, CDAI) and physical function (HAQ). Previous treatments.Statistical Analysis:descriptive, bivariate using x2 and T-Student among patients with and without relapse at 24 months and multivariate linear regression to identify independent variables associated with the time in BT dose reduction (DV: time in reduction).Results:59 patients with RA were included. Table 1 shows the main characteristics of the subjects. The average (SD) of optimization in months was 17.9 (17.7). Ten patients (16.9%) relapsed at 12 months and 16 (27.1%) at 24 months. The mean (SD) of DAS28 and SDAI of patients who relapsed at 24 months was higher compared to baseline DAS28 (2.3 [0.9] vs. 1.5 [0.8]; p = 0.015) and SDAI (7.8 [6.3] versus 3.3 [1.6]; p 0.05). These patients who relapsed at 24 months compared to patients who did not have more erosions at the start of BT (p = 0.004), longer duration of disease (p = 0.072) and greater baseline activity of DAS28 (p = 0.017), of SDAI (p = 0.030) and CDAI (p = 0.036). After simulating the REDOSER tool to all patients at the beginning of the OBT, 28 patients (56%) were “Appropriate”, 20 (40%) “Doubtful” and 2 (4%) “Inappropriate” of which they continue in OBT at the conclusion of study 22, 10 and 0, respectively (p = 0.020). In the multivariant analysis, the independent variables that are associated with time in dose reduction of BT were baseline DAS28 (β = -0.660, 95% CI[2.7-14.0]; p=0.014) and age (β=-0.800, 95% CI [0.8-0.0]; p=0.038).Conclusion:The majority of the patients with RA who initiate BT dose reduction maintain the optimization after 24 months. REDOSER can be useful in clinical practice to assess the BT optimization in patients with RA. A longer time in BT dose reduction was associated with lower values of DAS28 at the beginning and younger age of the patients.Figure 1:Disclosure of Interests:None declared

scholarly journals AB0182 EVALUATION OF THE SOCIO-PROFESSIONAL IMPACT OF ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS IN TUNISIA: DATA FROM THE BINAR REGISTRY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1390.2-1391
Author(s):  
H. Hachfi ◽  
N. Ben Chekaya ◽  
D. Khalifa ◽  
M. Brahem ◽  
H. Themri ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Marital Status ◽  
Biological Therapy ◽  
Total Duration ◽  
National Registry ◽  
Inflammatory Rheumatic Diseases ◽  
Physically Active ◽  
Absence From Work ◽  
Professional Impact

Background:Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are disabling and common chronic inflammatory rheumatic diseases.Objectives:The aim of our study was to evaluate the socio-professional impact of RA and AS.Methods:Using the Biological National Registry (BINAR) data, which includes ten tunisian rheumatology centers,we identified patients≥18 years with AS and RA according to the ACR and EULAR 2010 criteria(RA) and ASAS 2009 (AS), receiving biotherapy for less than two years.Results:298 patients were included in the study. The percentage of patients with RA was 58.7 % and those with AS 41.3%. The sex ratio was 0.6. The average age of the onset of the disease was 49.1 years ± 14.1 years [18–79]. For marital status, 72% were married, single (25%), widowed (2.6%) and divorced (0.4%). 22.4% of patients were illiterate, 32.7 % (primary), 28.3% (secondary) and 16.6% had an university level. For the RA population, a high disease activity (DAS28-ESR >5.1) was detected in 36% of patients, an erosive arthritis in 73.1% and 7.2% had a coxitis. In the AS group, an elevate BASDAI (BASDAI≥4) was detected in 56.9% of patients and 39% had coxitis. All patients have received Biological therapy concomitant with corticosteroids (59.1%), methotrexate (42.6%), salazopirine (20.8%) and leflunomide (4.7%). 54% of patients had a comorbidity, of which 1.7% was depression. More than half of our patients (54.3%) were unemployed, 40 % were professionally active, and 5.7% were retired due to the rheumatic condition. Absence from work was observed in 15.1% of cases with a total duration exceeding three months in 55.5% of cases. 37.9 % of patients were physically active: regularly (9.8%), irregularly (28.1%) and (62.1%) were sedentary. For the functional impact, HAQ score was 1.31± 0.7 for RA and BASFI was 5.2 ± 4.8 for AS. The working abandonment is significantly associated to: marital status (p=0.039), low level of education (p=0.04),depression (p<0.001), high activity of AS (p=0.004) and BASFI>4 (p=0,001).Conclusion:RA or AS requiring biotherapy have a high socio-economic impact and are responsible for absenteeism at work and even for early working abandonment. Early therapeutic management and a global assessment are essential in order to improve quality of life and working conditions. Longitudinal studies are needed to assess the effect of biological therapy on the socio-professional impact of these chronic inflammatory rheumatic disease.Disclosure of Interests:None declared

scholarly journals AB0237 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB AND ANTI-TNF INHIBITOR

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1144.2-1144
Author(s):  
N. Zehraoui ◽  
R. Benaziez.Boutaleb ◽  
H. Hafirassou ◽  
F. Mechid ◽  
N. Bahaz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Best Practice ◽  
Biological Therapy ◽  
Patient Characteristics ◽  
Inadequate Response ◽  
Tnf Inhibitor ◽  
Clinical Rheumatology ◽  
Number Of Patients ◽  
Serious Infections ◽  
Comparative Risk

Background:Biological therapies have significantly improved the management of rheumatoid arthritis (RA). These molecules are very effective, but are known for their specific risks, especially infectious. It depends on several factors including the type of molecule used.Objectives:The objective of our study is to compare the rate of infection in RA patients treated with rituximab and anti-TNFα.Methods:Prospective, observational, monocentric study. Were included RA patients (ACR / EULAR 2010 criteria) treated with rituximab and anti-TNFα (adalimumab, infliximab and Etanercept) after inadequate response to DMARDs.Demographic characteristics, comorbidities, association with methotrexate and corticosteroids were collected and compared for each group.The number, type and severity of the infections in both cases were noted.SPSS (Statistical Package for Social Science) was used for data analysis.Results:40 RA patients treated with rituximab and 31 patients who received anti-TNFα were included.Patient characteristics and Comparison of rate of infection in RA patients between the two groups are summarized in Table 1Table 1.ParametersRituximabAnti-TNFαpNumber of patients4031Average age (years)56,2846,060,01Sexratio0,140,110,7Average duration of evolution (years)15,8313,740,3Patients under corticosteroid (%)97,587,10,08Average corticosteroid dose6,415,480,3patients under methotrexate (%)37,545,20,5Diabetes (%)2016,10,7Patients with infection (%)32,551,60,1Number of infections18240,4Number of serious infections500,04Conclusion:The rate of infections in patients with RA treated with rituximab or anti-TNF was similar. However, the infections observed were more serious in patients with RA treated with rituximabReferences:[1]Fabiola Atzeni MD PhD and al. Infections and Biological Therapy in Patients with Rheumatic Diseases. IMAJ . VOL 18. march-APRIL 2016.[2]Huifeng Yun and al. Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. ARTHRITIS & RHEUMATOLOGY. Vol. 68, No. 1, January 2016, pp 56–66.[3]Manjari Lahiri and al. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Practice & Research Clinical Rheumatology (2015) 1-16.Disclosure of Interests:None declared

AB1078-HPR Telephone Follow-Up, Standardized To The Initiation of Biologic Therapy of Patients with Rheumatoid Arthritis (RA) in A Specific Unit of Biologic Therapy. Pilot Study

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 1300.2-1300 ◽  
Author(s):  
L. Cano-Garcia ◽  
S. Manrique-Arija ◽  
I. Ureña ◽  
N. Mena-Vazquez ◽  
M.C. Ordoñez-Cañizares ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Biologic Therapy ◽  
Specific Unit

scholarly journals A Pilot Study on Zinc Levels in Patients with Rheumatoid Arthritis

2011 ◽  
Vol 143 (2) ◽  
pp. 854-862 ◽  
Author(s):  
Artur Mierzecki ◽  
Dorota Strecker ◽  
Krystyna Radomska
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Zinc Levels
Sign in / Sign up

Export Citation Format

Share Document